Evidence map›Paper›PMID 20700529›Full record

ArticlePloS one2010

Calcineurin interacts with PERK and dephosphorylates calnexin to relieve ER stress in mammals and frogs.

Mariana Bollo, R Madelaine Paredes, Deborah Holstein, Nadezhda Zheleznova, Patricia Camacho, James D Lechleiter

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. A cellular atlas of calcineurin signaling.Biochimica et biophysica acta. Molecular cell research · 2023
    Review
  14. Article
  15. CaCell calcium · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mariana BolloInstituto de Investigación Médica Mercedes y Martín Ferreyra (INIMEC CONICET), Córdoba, Argentina.
R Madelaine Paredes
Deborah Holstein
Nadezhda Zheleznova
Patricia Camacho
James D Lechleiter
The University of Texas Health Science Center at San Antonio · USConsejo Nacional de Investigaciones Científicas y Técnicas · AR

Funding

ROLE OF CASPASE-2 IN OSTEOCOLAST APOPTOSIS AGE-EePENDENT OSTEOPOROSISP01AG019316 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HERMAN, BRIAN A. · 2001 to 2011
$11.3M
LUMINAL CONTROL OF CALCIUM RELEASE BY CALRETICULINR01GM055372 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI CAMACHO, PATRICIA · 1997 to 2005
$1.6M
NIA NIH HHS P01 AG019316NIA NIH HHS P01 AG19316-06NIGMS NIH HHS R01 GM055372NIGMS NIH HHS R01 GM55372
6 · The paper itself

Abstract

backgroundThe accumulation of misfolded proteins within the endoplasmic reticulum (ER) triggers a cellular process known as the Unfolded Protein Response (UPR). One of the earliest responses is the attenuation of protein translation. Little is known about the role that Ca2+ mobilization plays in the early UPR. Work from our group has shown that cytosolic phosphorylation of calnexin (CLNX) controls Ca2+ uptake into the ER via the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) 2b. METHODOLOGY/PRINCIPAL

findingsHere, we demonstrate that calcineurin (CN), a Ca2+ dependent phosphatase, associates with the (PKR)-like ER kinase (PERK), and promotes PERK auto-phosphorylation. This association, in turn, increases the phosphorylation level of eukaryotic initiation factor-2 alpha (eIF2-alpha) and attenuates protein translation. Data supporting these conclusions were obtained from co-immunoprecipitations, pull-down assays, in-vitro kinase assays, siRNA treatments and [35S]-methionine incorporation measurements. The interaction of CN with PERK was facilitated at elevated cytosolic Ca2+ concentrations and involved the cytosolic domain of PERK. CN levels were rapidly increased by ER stressors, which could be blocked by siRNA treatments for CN-Aalpha in cultured astrocytes. Downregulation of CN blocked subsequent ER-stress-induced increases in phosphorylated elF2-alpha. CN knockdown in Xenopus oocytes predisposed them to induction of apoptosis. We also found that CLNX was dephosphorylated by CN when Ca2+ increased. These data were obtained from [gamma32P]-CLNX immunoprecipitations and Ca2+ imaging measurements. CLNX was dephosphorylated when Xenopus oocytes were treated with ER stressors. Dephosphorylation was pharmacologically blocked by treatment with CN inhibitors. Finally, evidence is presented that PERK phosphorylates CN-A at low resting levels of Ca2+. We further show that phosphorylated CN-A exhibits decreased phosphatase activity, consistent with this regulatory mechanism being shut down as ER homeostasis is re-established. CONCLUSIONS/SIGNIFICANCE: Our data suggest two new complementary roles for CN in the regulation of the early UPR. First, CN binding to PERK enhances inhibition of protein translation to allow the cell time to recover. The induction of the early UPR, as indicated by increased P-elF2alpha, is critically dependent on a translational increase in CN-Aalpha. Second, CN dephosphorylates CLNX and likely removes inhibition of SERCA2b activity, which would aid the rapid restoration of ER Ca2+ homeostasis.

Indexed as

AnuraStress, PhysiologicalAnimalsApoptosisAstrocytesCalcineurinCalciumCalnexinCytosoleIF-2 KinaseEndoplasmic ReticulumEukaryotic Initiation Factor-2Gene Knockdown TechniquesHomeostasisHumansMiceCalcineurinCalciumCalnexineIF-2 KinaseEukaryotic Initiation Factor-2Tunicamycin

Identifiers

PMID20700529
PMCPMC2916823
OpenAlexW2072563743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.